Srisha Hebbar

Therapeutic Endoscopist. Love to share the good and bad of my endoscopy journey. More you teach and share, more you learn.

[Srisha Hebbar @Srisha_Hebbar]

https://t.co/n4oF5Rj62H

Sharing the details of the Stoke EURCP symposium. A great opportunity to discuss, share knowledge and learn from each other. Look forward for the interaction.

[Srisha Hebbar @Srisha_Hebbar]

@DrAshokGastro @Clipper124 @DouglasAdlerMD Totally agree. Our fistulotomy rate is 20-30%. We do early NKF and also use primary NKF in certain ampullary morphology. Quicker procedures/low complications. NKF is not a last resort, but a technique to be adopted early for an effective cannulation

[Srisha Hebbar @Srisha_Hebbar]

@gvraoaig Congratulations. Very well deserved

[Srisha Hebbar @Srisha_Hebbar]

Proud to share this work. Complications are inevitable in endoscopy, but how we respond to them, support our teams, and learn from them is a choice. I hope this is a useful read.@BritSocGastro @ESGE_news @PhilSmithIsBack

[Frontline Gastro @FrontGastro_BMJ]

Endoscopy complications don’t end when the procedure does. 🔎⚠️🧑‍⚕️

This @FrontGastro_BMJ article explores the implications of endoscopy complications and non-clinical management strategies — from team impact and communication to governance, learning and support. 📋💬

Essential reading for endoscopy units aiming to improve safety culture beyond technical outcomes.

Read more: https://t.co/ZMTxi16ELh

#Endoscopy #PatientSafety #Complications #ClinicalGovernance #QualityImprovement #FrontlineGastro #GItwitter #Gastroenterology #EndoscopyTraining #MedEd @bluewailiam @srisha_hebbar @BritSocGastro @my_UEG @AmCollegeGastro @DDWMeeting @ESGE_news @drkeithsiau @DrOmerAhmad @Dunnepdj @shraddha_gulati @CardiffGastro @DrBuHayee @poodocnisha @Sharm_Sub @PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman

[Srisha Hebbar @Srisha_Hebbar]

Highlight of the Stoke Complications in Endoscopy Symposium.

Not a technique. Not a guideline.

A palliative consultant Michael Blabber, reminding us to find humanity in pain. #GItwitter

[Srisha Hebbar @Srisha_Hebbar]

Timing isn’t just clinical. t’s human.”

Timing should be part of complex procedures consent.
👉 Ask: “Is there anything important coming up we should plan around?”
If complications lead to hospitalisation, the impact isn’t just physical. it’s psychological too.
#GItwitter

[Srisha Hebbar @Srisha_Hebbar]

In the UK, the nasobiliary drain (NBD) is less commonly used,but it can be a very effective tool.

Sharing a video demonstrating setup for jejunal loop distension in EUS-GJ using a nasobiliary drain + foot pump.

Simple setup. Controlled distension. #GItwitter

[Srisha Hebbar @Srisha_Hebbar]

We recently performed an EUS CDD in a small duct using the push-pull technique with wire traction. This reinforces the value of teamwork & debriefing. Sharing a video debrief with my colleague Roderick discussing the steps, challenges, and key learning points. #GITwitter

[Srisha Hebbar @Srisha_Hebbar]

@DrBloodandGuts @Mo_Shiha These little gems of ideas make a huge difference.

[Srisha Hebbar @Srisha_Hebbar]

At #SCIES2026, @drmwjames shared a message that every endoscopist should hear. Complications are not just statistics. Over a career, they become personal.

The goal is not perfection. It is safer decisions, better systems, and continuous learning. #GItwitter

[Srisha Hebbar @Srisha_Hebbar]

We are excited to announce our upcoming Endoscopy Symposiums at Stoke - a series of events focused on education, collaboration, and excellence in endoscopy.
More information will be shared soon. Please save the dates and join us at Stoke.@UHNMEndoscopy
@endoscopy_META
#GItwitter

[Prof John Leeds @NEndoscopy]

U.K. therapeutic EUS group effort

[Srisha Hebbar @Srisha_Hebbar]

@DrLakhtakia @drsridhars @AntonioFaccior6 @DarylRamai @GVanell5 @Belenmm271 @MBronswijkMD @gastro3570 @helpatologist

[Srisha Hebbar @Srisha_Hebbar]

We did this live EUS GB drainage in 2023 Endoport, for malignant obstruction with good patient outcomes. Now, it is good to see this study.
Management of ERCP Failure in Malignant Biliary Obstruction: Comparative Effectiveness and Safety of EUS GB Vs CDS. Dig Endosc. 2026

[Srisha Hebbar @Srisha_Hebbar]

Live case to #endoport2023 .
Panc ca, Duod stent insitu. ⬆️ Bil.
Attempted HGS. Due to large hiatus hernia, positioning was difficult. Track dilatation/stenting couldnt be done.
Cholecystogastrostomy done. Plan -If bili doesnt ⬇️, OGD scope thro 🔥 axios, wire,DPT stent CBD

[Srisha Hebbar @Srisha_Hebbar]

@drkeithsiau at Stoke complications symposium.
Our job is not to hold information back.
It is to make it understandable.
When patients get the right information, they make better decisions & become true partners in care.This is how trust is built. #SCIES2026 #GItwitter

[Srisha Hebbar @Srisha_Hebbar]

@gvraoaig Inspiring talk @gvraoaig . Watched it from other part of the World @docdhir

[Srisha Hebbar @Srisha_Hebbar]

Heard @amolbapaye make a simple but important point today. The real goal of innovation isn’t novelty, it’s propagation. Ideas only matter when they spread and improve practice.@Nareshbhat14 @docdhir #GItwitter #IndiaEUSsummit2026

[BSG @BritSocGastro]

We're delighted to congratulate BSG member Andreas Hadjinicolaou who is one of the winners of the ESGE Next Generation Award 2026 👏

Andreas is at the forefront of pioneering GI endoscopic research and will present his work at #ESGEDays2026 on 15 May in Milan

@avhadjinicolaou

[Srisha Hebbar @Srisha_Hebbar]

@rajibaji1983 @NEndoscopy @ib9994 @javlatif @SLEPTonline @HpbLeicester @DerbyPBunit @Innov_Medicine @SAGES_Updates @BehindTheKnife @roux_group @Augishealth @EAHPBA @ASiTofficial @IHPBA @EndoCollabcom @JAG_Endoscopy Totally agree. We see the benefit of having a surgeon who is a PB endoscopist in the team. The trainees also benefit significantly. @javlatif hope you are learning EUS as well. To train in ERCP/EUS & surgery will be difficult for many surgical trainees in the future

[Srisha Hebbar @Srisha_Hebbar]

@theliverdoc Congratulations! Looking forward to it. You are truly inspiring.

[NEJM @NEJM]

GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal.

Read the Review Article “GLP-1 Receptor Agonists” by Clifford J. Rosen, MD, and Julie R. Ingelfinger, MD, from @tuftsmedschool and the Maine Medical Center Institute for Research: https://t.co/D0XSLv7U8n